HC Wainwright Reiterates “Buy” Rating for Artelo Biosciences (NASDAQ:ARTL)

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 362.96% from the stock’s current price.

Separately, EF Hutton Acquisition Co. I raised Artelo Biosciences to a “strong-buy” rating in a research report on Tuesday, October 1st.

Artelo Biosciences Stock Down 1.8 %

NASDAQ ARTL opened at $1.08 on Wednesday. Artelo Biosciences has a 52 week low of $1.00 and a 52 week high of $1.75. The company has a 50 day moving average price of $1.16 and a 200 day moving average price of $1.28. The firm has a market cap of $3.49 million, a PE ratio of -0.38 and a beta of 1.35.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. On average, equities research analysts anticipate that Artelo Biosciences will post -2.41 earnings per share for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.